Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

Abstract : FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit patients with metastatic (MPC) and locally advanced unresectable (LAPC) pancreatic cancer. However, no criteria reliably identify patients with better outcomes.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02307162
Contributor : Laurent Jonchère <>
Submitted on : Monday, October 7, 2019 - 1:15:12 PM
Last modification on : Wednesday, October 9, 2019 - 1:37:17 AM

Identifiers

Citation

Francesco Leone, Angélique Vienot, Andrea Casadei-Gardini, Caterina Vivaldi, Astrid Lièvre, et al.. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clinical Colorectal Cancer, 2019, ⟨10.1016/j.clcc.2019.08.004⟩. ⟨hal-02307162⟩

Share

Metrics

Record views

23